Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT04875169 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Core Treatment Active Experimental: SHR0302 Dose#1
DRUG: Core Treatment Active Experimental: SHR0302 Dose#2
DRUG: Core Treatment Placebo Comparator: Placebo
DRUG: Extension Treatment Active Experimental: SHR0302 Dose#1
DRUG: Extension Treatment Active Experimental: SHR0302 Dose#2

Sponsor

Reistone Biopharma Company Limited